Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Age-adjusted association between selected characteristics and CA125 levels in Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO)

From: Development and validation of circulating CA125 prediction models in postmenopausal women

 Age-adjusted model
CharacteristicsN (%)Mean CA125 (U/mL) a% changep-value
Age
  < 60 years9388 (35)10.1 (10.0, 10.2)RefRef
 60–64 years8351 (31)10.4 (10.3, 10.5)3.6<.0001
 65–69 years5814 (22)10.7 (10.5, 10.8)5.8<.0001
  ≥70 years3428 (13)10.8 (10.6, 11.0)7.1<.0001
 p-trend   <.0001
Race
 White24,166 (90)10.6 (10.5, 10.7)RefRef
 Black1340 (5)8.0 (7.8, 8.3)−24<.0001
 Hispanic368 (1)9.2 (8.8, 9.7)−12.6<.0001
 Asian922 (3)10.0 (9.7, 10.3)−6.4<.0001
 Pacific Islander, Native American185 (1)9.2 (8.6, 9.9)−13.2<.0001
Body mass index
  ≤ 18.5 kg/m2283 (1)11.4 (10.8, 12.1)70.02
 18.5 < −25 kg/m210,778 (40)10.6 (10.5, 10.7)RefRef
 25 < −30 kg/m29408 (35)10.4 (10.3, 10.5)− 1.40.04
  > 30 kg/m26512 (24)10.0 (9.9, 10.1)−5.4<.0001
 p-trend   <.0001
Smoking
 Never15,288 (57)10.4 (10.4, 10.5)RefRef
 Current2471 (9)9.3 (9.1, 9.4)−10.8<.0001
 Former9222 (34)10.7 (10.6, 10.8)2.30.0004
Pack-years among current smokers
  < 1349 (2)8.5 (7.4, 9.7)RefRef
 13–30717 (29)9.1 (8.8, 9.5)7.40.33
  ≥ 301705 (69)9.3 (9.1, 9.5)10.10.18
 p-trend   0.003
Pack-years among former smokers
  < 133370 (37)10.5 (10.3, 10.7)RefRef
 13–302765 (30)10.5 (10.3, 10.7)−0.10.91
  ≥ 303087 (33)10.9 (10.7, 11.1)3.40.01
 p-trend   0.003
Age at first menstrual period
  < 10 years388 (1)9.8 (9.3, 10.3)−5.30.03
 10–11 years4870 (18)10.3 (10.1, 10.4)−1.60.05
 12–13 years14,703 (54)10.4 (10.4, 10.5)RefRef
 14–15 years5845 (22)10.5 (10.4, 10.6)0.10.85
  ≥ 16 years1153 (4)10.2 (10.0, 10.5)−2.20.15
 p-trend   0.18
Oral contraceptive use
 Never12,249 (45)10.4 (10.3, 10.5)RefRef
 Ever14,720 (55)10.4 (10.3, 10.5)1.00.11
Duration of oral contraceptive use among ever users
  < 1 year3892 (26)10.3 (10.2, 10.5)RefRef
 2–3 years3046 (21)10.2 (10.1, 10.4)−0.30.79
 4–5 years1989 (14) 10.2 (10.0, 10.4)−0.70.62
 6–9 years2450 (17) 10.3 (10.1, 10.5)0.70.58
  ≥ 10 years3315 (23)10.6 (10.4, 10.8)2.90.01
 p-trend   0.01
Parity
 02396 (9)10.1 (9.9, 10.3)RefRef
 11938 (7)10.0 (9.8, 10.2)−0.90.54
 26238 (23)10.5 (10.3, 10.6)4.10.001
 36692 (25)10.4 (10.3, 10.6)3.60.003
 44598 (17)10.6 (10.4, 10.7)4.20.001
  ≥ 55119 (19)10.4 (10.3, 10.6)2.60.03
 p-trend   0.02
Benign ovarian cyst
 No23,561 (90)10.4 (10.4, 10.5)RefRef
 Yes2689 (10)10.2 (10.0, 10.4)−2.00.05
Endometriosis
 No24,587 (94)10.4 (10.4, 10.5)RefRef
 Yes1610 (6)10.2 (10.0, 10.4)−1.30.17
Hysterectomy
 No19,597 (73)10.8 (10.7, 10.8)RefRef
 Yes7384 (27)9.5 (9.4, 9.6)−11.9<.0001
Age at last menstrual period
  < 40 years3655 (14)9.4 (9.2, 9.5)−11.8<.0001
 40–44 years3499 (13)10.0 (9.8, 10.2)−6.6<.0001
 45–49 years6092 (23)10.4 (10.3, 10.5)−2.90.0002
 50–54 years10,448 (39)10.7 (10.6, 10.8)RefRef
  ≥ 55 years3287 (12)11.2 (11.0, 11.4)5.3<.0001
 p-trend   <.0001
Time since menopause
  < 5 years3254 (12)10.6 (10.5, 10.8)RefRef
 5–9 years5120 (19)10.5 (10.4, 10.7)−4.9<.0001
 10–14 years5826 (22)10.5 (10.4, 10.6)−8.7<.0001
 15–19 years6356 (24)10.2 (10.1, 10.4)−12.9<.0001
  ≥ 20 years6425 (24)10.2 (10.1, 10.4)−17.4<.0001
 p-trend   <.0001
Hormone therapy use
 Never9493 (35)10.2 (10.1, 10.3)RefRef
 Ever17,488 (65)10.5 (10.4, 10.6)3.9<.0001
Duration of hormone therapy b
  ≤ 1 year3267 (19)10.3 (10.1, 10.5)RefRef
 2–3 years2860 (16)10.5 (10.3, 10.7)2.90.03
 4–5 years2508 (14)10.4 (10.2, 10.6)2.30.08
 6–9 years3421 (20)10.6 (10.5, 10.8)4.30.001
  ≥ 10 years5432 (31)10.6 (10.4, 10.7)1.80.11
 p-trend   0.15
Family history of ovarian cancer
 No25,471 (96)10.4 (10.3, 10.5)RefRef
 Yes1049 (4)10.3 (10.0, 10.6)−0.80.59
Family history of breast cancer
 No22,682 (86)10.4 (10.4, 10.5)RefRef
 Yes3837 (14)10.3 (10.1, 10.5)−1.30.12
Previous history of cancer
 No25,250 (94)10.4 (10.3, 10.4)RefRef
 Yes1731 (6)10.7 (10.4, 10.9)2.30.06
  1. a Geometric mean (5th, 95th percentile)
  2. b Among ever hormone therapy users